{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:12:53Z","timestamp":1778904773898,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clgc.2026.102543","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T16:26:04Z","timestamp":1774023964000},"page":"102543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Different Surveillance Intervals on Recurrence and Progression in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8493-8053","authenticated-orcid":false,"given":"Araz","family":"Musaev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c7a\u011fr\u0131","family":"Akp\u0131nar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timur K\u00fcr\u015fat","family":"\u00dclgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serhat","family":"Erkmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed Arif","family":"\u0130bi\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muratcan","family":"Karaburun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet \u0130lker","family":"G\u00f6k\u00e7e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6mer","family":"G\u00fclp\u0131nar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c7a\u011fatay","family":"G\u00f6\u011f\u00fc\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadir","family":"T\u00fcrk\u00f6lmez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4093-5436","authenticated-orcid":false,"given":"Evren","family":"S\u00fcer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00fcmer","family":"Baltac\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2026.102543_bib0001","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.clgc.2026.102543_bib0002","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non-muscle-invasive Bladder Cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group","volume":"5","author":"Tan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2026.102543_bib0003","series-title":"EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS)","author":"Gontero","year":"2025"},{"issue":"3","key":"10.1016\/j.clgc.2026.102543_bib0004","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol."},{"issue":"4","key":"10.1016\/j.clgc.2026.102543_bib0005","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2026.102543_bib0006","series-title":"NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer","volume":"2025","author":"Thomas","year":"2025"},{"issue":"4","key":"10.1016\/j.clgc.2026.102543_bib0007","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102543_bib0008","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) Prognostic Factor Risk Groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 Classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102543_bib0009","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.juro.2013.07.102","article-title":"Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition","volume":"191","author":"Lamm","year":"2014","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102543_bib0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/JU.0000000000001689","article-title":"Surveillance intensity in intermediate risk, nonmuscle invasive bladder cancer: revisiting the optimal timing and frequency of cystoscopy","volume":"206","author":"Bhat","year":"2021","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.clgc.2026.102543_bib0011","doi-asserted-by":"crossref","first-page":"E233","DOI":"10.5489\/cuaj.8552","article-title":"Efficacy and tolerability of bacillus Calmette-Guerin strain Russia for the treatment of non-muscle-invasive bladder cancer analysis of a prospective registry","volume":"18","author":"Flury-Sutter","year":"2024","journal-title":"Can Urol Assoc J."},{"issue":"1","key":"10.1016\/j.clgc.2026.102543_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102286","article-title":"Impact of BMI category on recurrence and progression of nonmuscle invasive bladder cancer prognosis","volume":"23","author":"Thomas","year":"2025","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2026.102543_bib0013","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","article-title":"Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer","volume":"192","author":"Kamat","year":"2014","journal-title":"J Urol."},{"issue":"9","key":"10.1016\/j.clgc.2026.102543_bib0014","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14490","article-title":"Impact of delay in cystoscopic surveillance on recurrence and progression rates in patients with non-muscle-invasive bladder cancer during the COVID-19 pandemic","volume":"75","author":"Culpan","year":"2021","journal-title":"Int J Clin Pract"},{"issue":"5","key":"10.1016\/j.clgc.2026.102543_bib0015","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/JU.0000000000003639","article-title":"International bladder Cancer Group intermediate-risk nonmuscle-invasive bladder cancer scoring system predicts outcomes of patients on active surveillance","volume":"210","author":"Tan","year":"2023","journal-title":"J Urol."},{"key":"10.1016\/j.clgc.2026.102543_bib0016","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.urology.2017.07.016","article-title":"The burden of cystoscopic bladder cancer surveillance: anxiety, discomfort, and patient preferences for decision making","volume":"108","author":"Koo","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2026.102543_bib0017","first-page":"33","article-title":"Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial","volume":"172","author":"Olsen","year":"1995","journal-title":"Scand J Urol Nephrol Suppl"},{"issue":"6","key":"10.1016\/j.clgc.2026.102543_bib0018","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.euo.2024.06.004","article-title":"Clinical validation of the intermediate-risk non-muscle-invasive Bladder Cancer scoring system and substratification model proposed by the International Bladder Cancer Group: a Multicenter Young Academic Urologists Urothelial Working Group collaboration","volume":"7","author":"Soria","year":"2024","journal-title":"Eur Urol Oncol."},{"issue":"5","key":"10.1016\/j.clgc.2026.102543_bib0019","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.urolonc.2017.12.016","article-title":"Implementing risk-aligned bladder cancer surveillance care","volume":"36","author":"Schroeck","year":"2018","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102543_bib0020","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.euo.2025.04.010","article-title":"Towards defining follow-up strategies for patients with primary intermediate-risk non-muscle-invasive bladder cancer","volume":"8","author":"Contieri","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102543_bib0021","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/iju.15162","article-title":"Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer: a multi-institutional collaborative study","volume":"30","author":"Miyamoto","year":"2023","journal-title":"Int J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102543_bib0022","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/bju.16780","article-title":"Contemporary outcomes in non-muscle-invasive bladder cancer: a large European multicentre study","volume":"136","author":"Longoni","year":"2025","journal-title":"BJU Int."},{"issue":"4","key":"10.1016\/j.clgc.2026.102543_bib0023","first-page":"669","article-title":"Optimal surveillance intensity of cystoscopy in intermediate-risk non-muscle invasive bladder cancer","volume":"54","author":"Wang","year":"2022","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:33:35Z","timestamp":1778902415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1558767326000431"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102543","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Different Surveillance Intervals on Recurrence and Progression in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102543"}}